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Abstract
Double homeobox 4 (DUX4), the causative gene of facioscapulohumeral muscular dystrophy (FSHD), is ectopically expressed
in the skeletal muscle cells of FSHD patients because of chromatin relaxation at 4q35. The diminished heterochromatic
state at 4q35 is caused by either large genome contractions [FSHD type 1 (FSHD1)] or mutations in genes encoding
chromatin regulators, such as SMCHD1 [FSHD type 2 (FSHD2)]. However, the mechanism by which DUX4 expression is
regulated remains largely unknown. Here, using a myocyte model developed from patient-derived induced pluripotent stem
cells, we determined that DUX4 expression was increased by oxidative stress (OS), a common environmental stress in
skeletal muscle, in both FSHD1 and FSHD2 myocytes. We generated FSHD2-derived isogenic control clones with SMCHD1
mutation corrected by clustered regularly interspaced short palindromic repeats (CRISPR)/ CRISPR associated 9 (Cas9) and
homologous recombination and found in the myocytes obtained from these clones that DUX4 basal expression and the
OS-induced upregulation were markedly suppressed due to an increase in the heterochromatic state at 4q35. We further
found that DNA damage response (DDR) was involved in OS-induced DUX4 increase and identified ataxia-telangiectasia
mutated, a DDR regulator, as a mediator of this effect. Our results suggest that the relaxed chromatin state in FSHD muscle
cells permits aberrant access of OS-induced DDR signaling, thus increasing DUX4 expression. These results suggest OS could
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Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is a geneti-
cally inherited disease that causes progressive weakness of the
skeletal muscle. FSHD type 1 (FSHD1) is caused by reduced
D4Z4 repeats (1–10 repeats) combined with permissive polymor-
phisms containing a polyadenylation (poly(A)) signal (PAS) at
the sub-telomeric region 4q35. Similarly, FSHD type 2 (FSHD2)
is caused by reduced D4Z4 repeats combined with permissive
polymorphisms containing a PAS at 4q35, but the repeats exceed
10, and mutations in chromatin regulators, including SMCHD1
(structural maintenance of chromosomes flexible hinge domain
containing 1), are also present (1–3). The genomic mutations in
both FSHD1 and FSHD2 result in chromatin relaxation at 4q35,
which is characterized by DNA hypomethylation and a reduction
in the levels of histone 3 lysine 9 trimethylation (H3K9me3) and
heterochromatin protein 1γ (HP1γ ). Thus, PAS stabilizes double
homeobox 4 (DUX4) transcripts to permit ectopic expression of
the gene (3–6). The aberrant DUX4 expression exerts toxic effects
in skeletal muscle cells through its transcriptional activity (7–9).
FSHD1 and FSHD2 patients show similar clinical phenotypes,
suggesting an identical molecular pathology (10).
FSHD shows unique clinical characteristics compared to
other types of muscular dystrophies including relatively late
onset of the disease phenotypes (typically during the second
decade), asymmetric patterns of muscle weakness and large
variations in disease progression among patients (11). This
variability in symptoms is partially explained by the approx-
imately inverse correlation between the number of D4Z4
repeats and clinical severity (12), but this explanation remains
incomplete because clinical variability is found even among
patients harboring the same number of D4Z4 repeats (13). Based
on a series of clinical and genetic studies, the current consensus
is that endogenous DUX4 expression plays a causative role in
FSHD pathogenesis; the varying clinical characteristics of the
disease would strongly support the existence of exogenous
factors that modulate the clinical phenotype by affecting events
upstream or downstream of DUX4 expression. Accordingly, a
recent study showed that estrogens could function in mediating
the sex-related differences in the disease by antagonizing DUX4
downstream events without altering DUX4 expression, thus pro-
tecting against the impaired differentiation of patient-derived
myoblasts (14). Regarding events upstream of DUX4, previous
pharmacological studies have identified several upstream regu-
lators of DUX4 (15–18), but no extracellular factor that increases
DUX4 expression has been reported so far. Moreover, the low-
level expression of DUX4 raises questions regarding its func-
tional impact; only extremely few cultured cells (1/1000 cells)
show detectable DUX4 expression at the translational level (19).
Furthermore, to date, no evidence has been reported of DUX4
protein expression in FSHD patient biopsies. However, endoge-
nous DUX4 expression was shown to be sufficient for inducing
cellular toxicity during the differentiation of myoblasts into
myotubes or for impairing the differentiation of pluripotent
stem cells into cells of skeletal muscle lineage (20,21). Thus, low
but substantial DUX4 expression in cultured cells derived from
distinct patients with FSHD appears to reflect differences in
clonal conditions and disease progression of the patients (19). In
addition,a recently reported rodent FSHDmodel showed that the
muscular pathological phenotype depends on DUX4 transgene
expression levels (22). A consideration of these findings led us
to hypothesize that an external factor modulates disease onset
and progression in FSHD patients through the transcriptional
regulation of DUX4.
Oxidative stress (OS) is one of the major stresses affecting
skeletal muscle function in the context of both homeostasis and
pathology (23,24). The involvement of OS in FSHD pathology is
supported by certain clinical and experimental studies. Clinical
studies have revealed that OS markers are elevated in FSHD
muscle as compared with the level in healthy muscle (25) and
that oral supplementation of antioxidants partially improves
muscle function in FSHD patients (26). In addition, the results of
in vitro experimental studies have shown that FSHD myoblasts
are vulnerable to H2O2 stimulation, a model of OS, and
that DUX4-induced endogenous OS contributes to aberrant
differentiation (27–29). Moreover, a series of transcriptomic
studies revealed that DUX4 altered the transcription of OS-
response genes (30–32). Thus, the findings obtained to date have
positioned OS downstream of DUX4 in FSHD pathology, but
the possibility that OS affects DUX4 expression by acting as
an upstream factor has not been investigated.
In the present study, using myocytes differentiated from
induced pluripotent stem cells (iPSCs) derived from both FSHD1
and FSHD2 patients, we demonstrated that OS increases DUX4
expression specifically in FSHD muscle cells. By using genome-
editing technology, we generated isogenic controls of FSHD2
iPSCs by correcting the SMCHD1 mutation; myocytes derived
from these isogenic controls showed suppressed basal DUX4
expression and partially recovered heterochromatic markers at
4q35. Notably, the OS-induced DUX4 increase was also sup-
pressed in these gene-corrected myocytes. Lastly, we attributed
the DUX4 increase by OS to aberrant access of DNA damage
response (DDR) signaling to the opened FSHD 4q35 region and
further identified ataxia-telangiectasia-mutated (ATM) kinase as
a mediator of this effect. These results suggest that OS could
represent an environmental risk factor that promotes FSHD
progression through the regulation of DUX4.
Results
Generation of iPStet-MyoD clones from FSHD1 and FSHD2
patients and a healthy control donor
Weprepared iPSCs fromone FSHD1patient harboring threeD4Z4
repeats (F1), one FSHD2 patient harboring an SMCHD1 mutation
(F2) and one healthy donor with no FSHD symptoms (HC) by
using a previously established method, in which episomal
vectors carrying the reprogramming factors Oct3/4, Sox2, Klf4
and L-Myc were transfected into skin fibroblasts of HC and F1
and blood cells of F2 (Supplementary Material, Table S1). To
obtain iPSCs possessing the potential to efficiently differentiate
into myocytes, we used a tetracycline-inducible MyoD piggyBac
vector (tet-MyoD) that was constructed previously; this enabled
the transfected iPSCs (iPStet-MyoD) to express MyoD, a master reg-
ulator gene for skeletalmuscle differentiation, and subsequently
to differentiate into myosin heavy chain (MyHC)-positive
myocytes only when Doxwas added to themedium (Fig. 1A) (33).
The expression of stage-specific embryonic antigen (SSEA)-4 and
tumor-related antigen (TRA)-1–60, which are indicators of un-
differentiated pluripotent stem cells, was detected by immuno-
cytochemistry, demonstrating that the iPStet-MyoD clones retained
undifferentiated pluripotent characteristics (Fig. 1B; Supplemen-
tary Material, Fig. S1A). To model myocytes, myogenic differ-
entiation was performed on these iPStet-MyoD clones through
Dox-inducible MyoD overexpression. On day 8, >80% of the
nuclei were positioned inside MyHC-positive cells in each clone,
indicating that comparable myocyte lineage was induced from
two iPStet-MyoD clones from each donor (HC#1, HC#2, F1#1, F1#2,
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Figure 1. iPStet-MyoD clones were generated from a healthy control and from FSHD1 and FSHD2 patients. (A) Scheme of the differentiation of iPSC clones to
myocytes. (B) Representative images of immunofluorescence staining of SSEA4 (red) and TRA-1-60 (yellow) in undifferentiated iPSCtet-MyoD clones. Scale bar: 500 μm.
(C) Representative images of immunofluorescence staining of MyHC (green) in differentiated myocytes at day 8. Scale bar: 500 μm. (D) Differentiation efficiency was
quantified by calculating the percentage of MyHC positive nuclei in total nuclei at day 8 (n = 4). (E–H) RT-qPCR analysis of all clones at day 0 (undifferentiated) and day
8 (differentiated) (n = 3) for (E) pluripotency markers, (F) myogenic markers, (G) DUX4 and its downstream targets and (H) ACTB as a reference gene. Relative expression
levels were normalized to RPLP0 as an internal control in each sample and then to F1#1 at day 8 (differentiated). Data information: in (D–H), data are represented as
mean ± standard error of the mean.
and C). The results of the reverse-transcription quantitative
polymerase chain reaction (RT-qPCR) analysis for pluripotency
markers (OCT3/4, NANOG and SOX2) and muscle-lineage mark-
ers (MYOG, MYH3 and CKM) confirmed the efficient myogenic
differentiation of each cell line (Fig. 1E and F; Supplementary
Material, Fig. S1D and E). Moreover, RT-qPCR analysis for DUX4
and its reported downstream targets (ZSCAN4, TRIM43 and
MBD3L2) revealed considerably higher expression of these
molecules in the differentiated state than in the undifferentiated
state in the F1 and F2 clones but not in the HC clone (Fig. 1G;
Supplementary Material, Fig. S1F). The expression of ACTB,
which we used as another reference gene, was almost com-
parable between the undifferentiated and differentiated states
(Fig. 1H; Supplementary Material, Fig. S1G). In the case of the
F1#1 clone, DNA methylation analysis specific for the allele
harboring short D4Z4 repeats revealed that DNA methylation
was stably low during the reprogramming from fibroblasts to
iPSCs or differentiation from iPSCs to myocytes as compared to
the healthy level (> 26%) reported previously by using the same
methods (Fig. S2) (34). These data suggested that the myocytes
differentiated from the human iPSC clones were suitable for
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Figure 2. OS increased DUX4 expression in FSHD myocytes. (A) RT-qPCR was performed for DUX4, its downstream targets (ZSCAN4, TRIM43 and MBD3L2) and MYH3
in HC#1, HC#2, F1#1, F1#2, F2#1 and F2#2 myocytes incubated with or without 100 μM H2O2 for 24 h at day 8 after differentiation (n = 3 for each condition). Relative
expression levels were normalized to RPLP0 as an internal control in each sample and then to F1#1 without H2O2. (B) RT-qPCR was performed for DUX4 and ZSCAN4
in F1#1 and F2#1 myocytes incubated with 2-mercaptoethanol (2-ME) or with H2O2 at various concentrations for 24 h at day 8 after differentiation (n = 3 for each
condition). Relative expression levels were normalized to RPLP0 as an internal control in each sample and then to the condition with 0 μM H2O2 without 2-ME in
each clone. (C) NAC was pretreated 1 h before H2O2 stimulation to F1#1 myocytes at day 8. 24 h after H2O2 addition, RT-qPCR was performed for DUX4 and ZSCAN4
(n = 3 for each condition). Relative expression levels were normalized to RPLP0 as an internal control in each sample and then to the condition without H2O2 or NAC.
(D) Time-course analysis of DUX4 and ZSCAN4 mRNA expression by RT-qPCR after H2O2 stimulation (n = 3 per each time point). Relative expression levels were
normalized to RPLP0 as an internal control in each sample and then to the condition with 0 μM H2O2. Data information: all data are represented as mean ± SEM.
*P ≤ 0.05, *P ≤ 0.01 [Student’s t-test in (A) and (C), one way ANOVA followed by Dunnett’s Multiple Comparison Test in (B)].
OS increased DUX4 expression in both FSHD1 and
FSHD2 myocytes
To investigate whether OS increases DUX4 expression, we stim-
ulated myocytes with H2O2, which served here as an OS model.
RT-qPCR analysis ofDUX4mRNAexpression inmyocytes showed
that H2O2 stimulation for 24 h, which is physiologically mild to
allow cell survival (for more than 80%), significantly increased
the transcription of DUX4 and its targets, a phenomenon not
observed in the healthy control (Fig. 2A; SupplementaryMaterial,
Fig. S3). The H2O2 stimulation did not increase the MYH3
level, indicating that the DUX4 increase was not because of
accelerated myogenic differentiation, as DUX4 expression is
known to increase after myogenic differentiation (Fig. 2A). F1#1
and F2#1 myocytes showed an almost dose-dependent increase
of DUX4 expression and transcriptional activity (Fig. 2B).
Conversely, treatment with NAC, an antioxidant, attenuated the
DUX4 increase induced by H2O2, indicating that the OS caused by
H2O2 stimulationwas responsible for theDUX4 increase (Fig. 2C).
Time-course analysis further revealed that the increase of DUX4
transcription started between 6 and 12 h after H2O2 stimulation,
suggesting that an early response to OS mediates the increase
in transcription (Fig. 2D). The increase of ZSCAN4 occurred later
than the increase of DUX4, suggesting that the DUX4 increase
was because of an increase in the amount of transcription per
cell, not because of selection for the population with higher
DUX4 expression (Fig. 2D). In contrast, F1 fibroblasts did not
express DUX4 regardless of H2O2 stimulation (Supplementary
Material, Fig. S4). These data demonstrated that OS increased
DUX4 expression in FSHD muscle cells.
DUX4 expression in FSHD2 isogenic control clones
showed basal suppression and resistance to OS
To ascertain whether the OS-induced DUX4 increase was a
disease-specific event, we generated isogenic control cell
lines by correcting the SMCHD1 mutation in F2#1 iPStet-MyoD
cells by using the CRISPR/Cas9 system together with donor
template vectors for homology-directed repair (Fig. 3A). Patient
F2 carried a heterozygous mutation with a 15 bp deletion and
1 bp substitution in exon 32 of SMCHD1, which was modified
to generate two isogenic clones (IC#1 and IC#2) in which the
mutations were replaced with the wild-type sequence (Fig. 3A
and B). These isogenic clones retained the expression of
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differentiate into MyHC-positive myocytes (Fig. 3C–E and G–H).
SMCHD1 protein expression was increased in isogenic control
myocytes compared to parental F2#1 myocytes, indicating
haploinsufficiency of SMCHD1 in the parental clone myocytes
(Fig. 3F). In IC#1 and IC#2 myocytes, DUX4 and its downstream
targets were expressed at substantially lower levels than in
parental clone F2#1myocytes, indicating that the SMCHD1muta-
tion was responsible for the basal DUX4 transcription in these
F2 myocytes (Fig. 3I). Comparable ACTB expression confirmed
these observations (Fig. 3J). Moreover, the myocytes differen-
tiated from the isogenic control clones showed only a slight
increase in DUX4 expression following H2O2 stimulation, and
the expression level in the isogenic control clones treated with
the highest concentration of H2O2 was still lower than that
in the parental clone without stimulation (Fig. 3K; Supplemen-
tary Material, Fig. S5A). Together, these data indicate that the
DUX4 expression level and its marked OS-induced increase were
dependent on the disease-causing SMCHD1 mutation in FSHD2.
Heterochromatic status at 4q35 was partially increased
in F2 isogenic control myocytes
FSHD 4q35 is characterized by chromatin relaxation through
DNA hypomethylation and reduced levels of H3K9me3 and HP1γ
(4,5). Unexpectedly, DNA methylation in the 4qA allele was not
significantly increased after the gene correction (Fig. 4A; Sup-
plementary Material, Fig. S5B). However, chromatin immuno-
precipitation (ChIP) followed by RT-qPCR analysis revealed that
the accumulation of H3K9me3 and HP1γ had increased in the
D4Z4 regions in isogenic control myocytes, whereas H3K4me2,
which we used as a transcriptional activation marker, was not
significantly altered (Fig. 4B; Supplementary Material, Fig. S5C).
Moreover, SMCHD1 accumulation was also increased in isogenic
control myocytes, indicating SMCHD1 haploinsufficiency at the
D4Z4 region in the F2 clone (Fig. 4B; Supplementary Material,
Fig. S5C). These data indicated that a reduction of heterochro-
matic histonemodification underlays theDUX4 basal expression
and increase by OS in FSHD myocytes.
DDR occurred before DUX4 increase under OS
Because H2O2 stimulation exerts a broad range of effects on cells
including DNA damage (23,35), we next investigated whether
DDR was involved in the OS-induced increase of DUX4. At 6 h
after H2O2 stimulation, when DUX4 expression was not yet
affected by H2O2 in FSHD myocytes (Fig. 2D), the expression of
γ -H2AX, an indicator of DDR, was increased in each clone
similarly (Fig. 5A and B). For F1#1 myocytes, the expression of
γ -H2AX showed an H2O2 dose-dependent increase (Fig. 5C and
D). These data indicate that the DDR by OS occurs prior to DUX4
increase in FSHD myocytes.
Other genotoxic stresses increased DUX4 expression in
FSHD myocytes
Moreover, because ultraviolet C (UV-C) exposure inducesDDR,we
examined its effect and found that a short exposure of myocytes
to UV-C (such thatmost cells survived for 24 h) also increased the
expression ofDUX4 and its targets, but not ofMYH3 (Supplemen-
tary Material, Fig. S6A–C). The expression of γ -H2AX was sim-
ilarly increased in each clone before UV-C affected DUX4 tran-
scription (SupplementaryMaterial, Fig. S6D and E).We examined
whether DNA damage alone is sufficient to induce the DUX4
increase using mitomycin C (MMC), a DNA damage inducer.
Myocytes treated with MMC also showed an increased expres-
sion of DUX4 and its targets, but not ofMYH3 (Fig. 6A and B). F1#1
myocytes showed an MMC dose-dependent increase of DUX4
expression and transcriptional activity (Fig. 6C). The expression
of γ -H2AX was increased in each clone similarly before MMC
affected DUX4 transcription (Fig. 6D and E). These data indicated
that genotoxic stresses could increase DUX4 expression in FSHD
myocytes.
OS indirectly increased DUX4 through ATM-mediated
DDR
DDR is primarily controlled by three phosphoinositide 3-kinase-
related kinases: ATM, ATM and Rad3-related (ATR) and DNA-
dependent protein kinase (DNA-PK) (36,37). To identify the
kinase that is responsible for OS-induced DUX4 increase, F1#1
myocytes were stimulated with H2O2 in the presence or absence
of specific kinase inhibitors. Whereas the inhibition of ATR or
DNA-PK did not markedly affect DUX4 expression, the inhibition
of ATM attenuated the DUX4 increase induced by H2O2 in a
concentration-dependent manner (Fig. 7A). Moreover, treatment
with the ATM inhibitor caused a decrease in the number of
γ -H2AX-positive nuclei under the OS condition in F1 myocytes,
which indicated that the DDR triggered by H2O2 stimulation was
prevented by ATM inhibition (Fig. 7B and C). Although OS can
directly activate members of the stress-induced MAP kinase
family to regulate gene expression (23,38), the inhibition of
MEK, JNK or p38 MAPK did not suppress the OS-induced DUX4
increase; therefore, this increase appeared not to be a direct
outcome of stress responses (Supplementary Material, Fig. S7A).
Lastly, the DUX4 increase in F2#1 myocytes under the OS con-
dition was also attenuated by the ATM inhibitor (Fig. 7D) and
inhibition of ATM did not decrease expression of DUX4 and
ZSCAN4 in FSHD myocytes in the absence of OS (Supplementary
Material, Fig. S7B and S7C).Overall, these data indicated thatDDR
mediates the OS-inducedDUX4 increase through ATM activation
in FSHD myocytes.
Discussion
FSHD is caused by genetic disorders but shows variations in
disease progression among patients, suggesting the existence of
certain external factors that modulate the pathological condi-
tion. Using patient iPSCs, this study has demonstrated, to our
knowledge for the first time, that the expression of DUX4, the
gene primarily responsible for FSHD pathology, is increased by
external cellular stress. Furthermore, we have shown that the
DUX4 increase induced by OS is mediated by the DDR signaling
pathway, which suggests that diverse types of genotoxic stress
can increase DUX4 expression and could therefore represent risk
factors for FSHD onset or progression.
The involvement of OS in FSHD pathology has been previ-
ously reported by several groups. DUX4-expressing muscle cells
showed transcriptome enrichment in OS-related gene expres-
sion (30–32). Moreover, exogenous DUX4 expression in mouse
myoblasts or human immortalizedmyoblasts resulted in vulner-
ability to OS (28,39). Endogenous DUX4 expression in immortal-
ized FSHDmyoblasts also led to vulnerability to OS and provoked
the production of endogenous reactive oxygen species (ROS)
followed by DDR to cause partial failure in differentiation (29).
However, these findings regarding the association of OS with
FSHD provide insights only into the downstream consequences
of DUX4 expression. In contrast, our results suggest OS and DNA
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Figure 3. Basal DUX4 expression and increased DUX4 expression by OS were suppressed by gene modification in FSHD2 myocytes. (A) Scheme of the gene correction
of the SMCHD1 mutation (shown in red letters) in F2 clone. The expected sequence (equal to wild-type sequence) after correction is shown in bold black letters. (B) The
sequence around the mutation site was checked. F2#1 clone has a heterozygous 15 bp deletion followed by one point mutation (A), resulting in an ambiguous signal
pattern, but genetically modified IC#1 and IC#2 clones showed a single pattern consistent with the expected sequence shown in (A), confirming the right correction.
(C) Representative images of immunofluorescence staining of SSEA4 (red) and TRA-1-60 (yellow) in undifferentiated iPSCtet-MyoD clones of IC#1 and IC#2. Scale
bar: 500 μm. (D) Representative images of immunofluorescence staining of MyHC (green) in differentiated myocytes at day 8 of IC#1 and IC#2. Scale bar: 500 μm.
(E) Differentiation efficiency was quantified by calculating the percentage of MyHC positive nuclei in total nuclei at day 8 (n = 4). (F) Representative result of western
blotting analysis for SMCHD1 (upper panel) and β-Actin (lower panel) in the myocytes of each clone at day 8. The lowest graph shows quantification of relative band
intensity. Band intensity of SMCHD1 was normalized to that of β-Actin and subsequently to F2#1 (n = 3). (G–J). RT-qPCR analysis of all clones on day 0 (undifferentiated)
and day 8 (differentiated) (n = 3) for (G) pluripotency markers, (H) myogenic markers, (I) DUX4 and its downstream targets and (J) ACTB as a reference gene. Relative
expression levels were normalized to RPLP0 as an internal control in each sample and subsequently to F2#1 at day8 (differentiated). (K) Differentiated myocytes at
day 8 after induction from F2#1 and IC#1 clones were incubated with or without H2O2 for 24 h, and RT-qPCR was performed for DUX4 and ZSCAN4 (n = 3 for each
condition). Relative expression levels were normalized to RPLP0 as an internal control in each sample and then to F2#1 without H2O2. Data information: in (E–K)
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Figure 4. The 4q35 genome in FSHD2 isogenic control myocytes showed a more
heterochromatic state at the protein level. (A) DNA methylation analysis on the
4q35 region by bisulfite sequencing. White and black circles mark unmethy-
lated and methylated CpG, respectively. The lower quartile (Q1) and range of
the percent methylation are shown above each column. (B) ChIP RT-qPCR was
performed on 4q35 for H3K9me3, H3K4me2 (as a negative control), HP17 and
SMCHD1 (n = 4). Relative % input was normalized to F2#1. Data information:
all data are represented as mean ± SEM. *P < 0.05, **P < 0.01 (Student’s t test,
unpaired).
in FSHD. Collectively, these findings indicate that a positive-
feedback loop in signaling cascades could be formed among OS,
DNA damage and endogenous DUX4 expression. During myo-
genic differentiation in mouse and human myoblasts, transient
DNA strand breakage is followed by the formation of γ -H2AX foci
(40,41). This effect might underlie the ‘burst’ of DUX4 expression
in a limited population of FSHDmyoblasts during differentiation
(20). In the context of differentiated muscle cells, which are
recognized to be resistant to diverse stressors (42,43), including
H2O2 and DNA damage inducers, DNA damage can be accumu-
lated without cell death by suppressing the p53-mediated apop-
tosis pathway (42,43). This effectmight contribute to the increase
in DUX4 expression induced in muscle fibers by OS and other
genotoxic stresses. Thus, OS and DNA damage are likely to influ-
ence FSHDpathology through the regulation ofDUX4 expression.
ATM performs multiple functions in DDR signaling at DNA
lesion sites, including transcriptional regulation and DNA repair.
We propose that the diminished heterochromatic state at the
4q35 region, characterized by a reduction of H3K9me3 and
HP1γ , increases the region’s sensitivity to DNA damage-induced
ATM activity, which results in DUX4 increase. A considerable
amount of evidence has implicated chromatin compaction in the
regulation of ATM activity. HDAC inhibition in human fibroblasts
permits an ATM-mediated transcriptional upregulation of MCL1
and Gadd45α, which are ATM targets, through the recruitment
of E2F1 transcription factor (44). In the context of DNA repair,
heterochromatin serves as a barrier to the expansion of ATM-
dependent γ -H2AX (45,46). Moreover, a decrease in chromatin
compaction,which can be induced by reducing the level of linker
histone H1, enhances resistance to DNA damage through an
increased accessibility of DDR factors to the lesion sites (47).
Thus, we suggest that non-FSHD 4q35 is transcriptionally
silenced and is less sensitive to the DNA damage-induced
Figure 5. DDR occurred after H2O2 stimulation but before DUX4 expression
increased. (A) Representative images of immunofluorescence staining of MyHC
(green) and 7-H2AX (red) in HC#1, F1#1, F2#1 and IC#1 myocytes at day 8 in the
presence or absence of H2O2. Cells were fixed 6 h after H2O2 addition. Scale bar:
100 μm. (B) The percentages of 7-H2AX positive nuclei in total nuclei in (A) (n= 3).
(C) Representative images of immunofluorescence staining of MyHC (green) and
7-H2AX (red) in F1#1 myocytes at day 8 incubated with 2-ME or with H2O2 at
various concentrations for 6 h. Scale bar: 100 μm. (D) The percentages of 7-H2AX
positive nuclei in total nuclei in (C) (n = 3). Data information: in (B) and (D), data
are represented as mean ± SEM. *P ≤ 0.05 [Student’s t-test in (B)].
ATM-mediated transcriptional machinery, whereas FSHD 4q35
permits the ATM-mediated machinery to access the lesion site
(Supplementary Material, Fig. S8).
Notably, in our FSHDmodels, activity of DUX4was dependent
on myogenic differentiation in both types of FSHD and was
associatedwith a disease-relatedmutation on SMCHD1 in FSHD2
(Fig. 1G and 3I), which indicates that our models are useful for
further FSHD pathological studies. Isogenic controls generated
for the FSHD2 clone showed robust suppression of endogenous
DUX4 expression,which agrees with previous genetic studies (6).
Intriguingly, SMCHD1 was found to recover the heterochromatic
state according to the level of a protein marker (although the
level was still lower than that in the healthy control; data not
shown), but not in terms of the DNA methylation level (Fig. 4).
This observation indicates that the DNA methylation status,
once determined, remains stable and is resistant to post-
developmental modification by epigenetic factors, whereas
alterations of heterochromatic protein markers are sufficient
to suppress DUX4 expression at 4q35. This finding supports the
modification of histone markers as a therapeutic strategy for
FSHD.
Although the expression of DUX4 in FSHD myocytes
upregulated downstream transcriptional targets, we did not
observe marked phenotypic changes, including apoptosis or
impaired differentiation, which apparently disagrees with
previous reports (15,21). We propose two possible reasons for
this phenotypic absence. The first is that the survival duration
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Figure 6. MMC exposure increased DUX4 expression. (A) Scheme of the MMC exposure. Differentiated myocytes at day 8 after induction were exposed to MMC for
2–2.5 h, incubated for 9 or 24 h and analyzed. (B) RT-qPCR was performed for DUX4, its downstream targets (ZSCAN4, TRIM43 and MBD3L2), and MYH3 in HC#1, F1#1,
F2#1 and IC#1 myocytes exposed to MMC for 2.5 h and subsequently incubated for 24 h (n = 3 for each condition). Relative expression levels were normalized to
RPLP0 as an internal control in each sample and then to F1#1 without UV-C exposure. (C) RT-qPCR was performed for DUX4 and ZSCAN4 in F1#1 myocytes exposed
to MMC at various concentrations for 2 h and subsequently incubated for 24 h (n = 3 for each condition). Relative expression levels were normalized to RPLP0 as an
internal control in each sample and then to the condition without MMC exposure. (D) Representative images of immunofluorescence staining of MyHC (green) and
7-H2AX (red) in HC#1, F1#1, F2#1 and IC#1 myocytes at day 8 exposed to MMC for 2.5 h. Cells were fixed for 9 h after the initiation of MMC exposure. Scale bar: 100 μm.
(E) The percentages of 7-H2AX positive nuclei in total nuclei in (C) (n = 3). Data information: in (B), (C) and (E), data are represented as mean ± SEM. *P ≤ 0.05, **P ≤ 0.01,
***P ≤ 0.001 [Student’s t-test in (B) and (E)].
notable phenotypic changes under the mild OS conditions used
in this study. A higher H2O2 concentration therefore may be
recommended but at the same time risks cell death indepen-
dently of DUX4 expression (Supplementary Material, Fig. S3).
Instead, a more mature muscle lineage showing longer survival
would be preferred. The second is that the myocytes induced in
our model system, which was shown to mimic the embryonic
myogenic lineage, might maintain resistance to DUX4 activity.
Given that DUX4 expression is detected even in the FSHD embryo
and that the disease phenotypes manifest long after birth in
most FSHD cases (48), embryonic myocytes might be capable
of tolerating DUX4 expression. To investigate this possibility, a
more mature state of muscle cells could be useful.
In accordance with previous studies, our findings indicate
that increased OS is a risk factor for FSHD patients. The elevated
OS could potentially be attenuated through supplementation
with ROS scavengers or even by including anti-oxidative nutri-
ents in the daily diet. Overall, our study has revealed, by using
patient-derived iPSCs, a previously unrecognized mechanism by
which DUX4 expression is regulated in FSHD muscle cells. This
finding could provide a basis for drug development and discovery
of therapeutic targets for FSHD.
Materials and Methods
Ethical approval
This study was approved by the Ethics Committee of the Grad-
uate School of Medicine, Kyoto University and the Kyoto Uni-
versity Hospital (Approval numbers #R0091 and #G259) and was
conducted according to the guidelines of the Declaration of
Helsinki. To protect confidentiality, all patient information were
kept anonymous, and a written informed consent was obtained
from the study participants.
Cell line and cell culture
Human dermal fibroblasts were donated by one Japanese male
FSHD1 patient and one healthy donor. Human blood cells were
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Figure 7. ATM inhibition suppressed DUX4 increase by OS. (A) RT-qPCR was
performed for DUX4 and ZSCAN4 in F1#1 myocytes under H2O2 stimula-
tion treated with KU-55933, VE-821 or NU-7441 (inhibitors for ATM, ATR or
DNA-PK, respectively) (n = 3 for each condition). Relative expression levels
were normalized to RPLP0 as an internal control in each sample and then
to the condition with 0 μM H2O2. Dimethyl sulfoxide (DMSO) was added
to each sample to keep its final concentration comparable among all con-
ditions. (B) Representative images of immunofluorescence staining of MyHC
(green) and 7-H2AX (red) in F1#1 myocytes in the absence or presence of
100 μM H2O2 and 20 μM KU-55933 (KU). DMSO was added to each sam-
ple to keep its final concentration comparable among all the conditions.
(C) The percentages of 7-H2AX positive nuclei in total nuclei in (B) (n = 3).
(D) RT-qPCR was performed for DUX4 and ZSCAN4 in F2#1 myocytes under
H2O2 stimulation and treated with KU-55933 (n = 3 for each condition). Relative
expression levels were normalized to RPLP0 as an internal control in each sample
and then to the condition with 0 μM H2O2. DMSO was added to each sample to
keep its final concentration comparable among all conditions. Data information:
in (A), (C) and (D), data are represented asmean± SEM. *P≤ 0.05 [one-way ANOVA
followed by Dunnett’s Multiple Comparison Test in (A), (C) and (D)].
clinical information is listed in Supplementary Table S1. All
human iPSCs used in this studywere established by overexpress-
ing four transcription factors by using an episomal vector and
were maintained on inactivated mouse feeder cells, as previ-
ously described (33), in primate embryonic stem (ES) cellmedium
(ReproCELL, Japan) supplemented with 4 ng/mL recombinant
human basic fibroblast growth factor (Oriental Yeast, Japan).
Generation of iPStet-MyoD clones
To prepare iPStet-MyoD clones (iPSCs that express MyoD in
response to doxycycline), the MyoD element was cloned into
the PB-TAC-ERN vector by using Gateway cloning to generate
PB-MyoD as previously described (33). iPSCs were transfected
with plasmids, including PBase and PB-MyoD, by using a NEPA21
electroporator (Nepagene, Japan) and plated on mouse feeder
cells for clone selection and culture maintenance as previously
described (49).
Myocyte differentiation
iPStet-MyoD cells were treated with accutase (Nacalai Tesque,
Japan) to separate them into single cells and plated at a density
of 3–5 × 105 cells/well in 6-well dishes coated with Matrigel
(BD Biosciences, USA) in primate ES cell medium supplemented
with 100 μg/mL neomycin sulfate (Nacalai Tesque) and 10 μM
Y-27632 (Nacalai Tesque). On the following day, the culture
medium was replaced with primate ES cell medium containing
1–2.5 μg/mL doxycycline (Dox; LKT Laboratories, USA). Induc-
tion was performed in 5% KSR/α-MEM containing Dox and
2-mercaptoethanol (2-ME) supplement for 5–7 days. Dox was
removed at least 1 day before harvest for gene expression study.
Correction of SMCHD1 mutation in iPSCs
The mutation in SMCHD1 was corrected through homologous
recombination (HR)-mediated knock-in using the CRISPR/Cas9
system (CRISPR and Cas9 endonuclease system) as described
in (50). Briefly, the single-guide RNA (sgRNA) sequence was
designed for an intron site near the mutation site by using
CRISPRdirect online software (http://crispr.dbcls.jp/) (51) and
cloned into pHL-H1-ccdB-mEF1a-RiH (Addgene ID: 60601). For
the HR template, bilateral 1 kb regions interposing the sgRNA
target site with the mutation in exon 32 replaced by the wild-
type sequence were cloned and inserted before and after the
puromycin-resistance gene element with two loxP sites in
pENTR-Donor-MCS2. The sgRNA vector, the HR vector and
pHL-EF1a-SphcCas9-iP-A (Addgene ID: 60599) were cotrans-
fected using a NEPA21 electroporator into F2 iPStet-MyoD cells.
Subcloning was performed after drug selection for 1 week.
Among the obtained clones, those harboring the homozygous
HR-derived sequence were selected and transfected with a Cre
recombinase construct, and subcloning was again performed to
select the clones that had lost the puromycin resistance. Lastly,
the sequence was confirmed to contain only one loxP site in
each allele. The primers used in these procedures are listed in
Supplementary Table S2.
Immunofluorescence analysis
Cultured cells were fixed with 2% formaldehyde in phosphate
buffered saline (PBS),washed in PBS, refixedwith 100%methanol
and blocked with Blocking One solution (Nacalai Tesque) at 4 ◦C.
Fixed samples were incubated overnight at 4 ◦C with primary
antibodies diluted in 10% Blocking One/PBST [PBS containing
0.2% Triton X-100 (Santa Cruz, USA)], washed repeatedly with
PBST and incubated for 1 h with secondary antibodies (diluted
in 10% Blocking One/PBST) and the nuclear stain DAPI (Sigma;
1:5000). Samples were examined, and images were captured
using a BZ9000 system (Keyence, Japan) at 200× and 400× mag-
nification. The antibodies used in this study are listed in Sup-
plementary Table S3.Myocyte differentiation efficiency is shown
as the percentage of nuclei within MyHC-positive areas in total
nuclei per field.
RNA extraction and real-time RT-qPCR
Total RNAwas extracted using a ReliaPrep RNAMiniprep System
(Promega) as per the manufacturer’s instructions. cDNA was
synthesized from the extracted RNA by using ReverTra Ace
Master Mix with gDNA Remover (TOYOBO, Japan). Real-time
RT-qPCR was performed using SYBR Green probe sets (Applied
Biosystems, USA) and a Step One Plus thermal cycler (Applied
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RPLP0, which encodes a ribosomal protein, was used as the
internal control in all assay. The primer sets used in this study
are listed in Supplementary Table S4.
Protein extraction and western blotting
Cultured cells were washed with PBS and collected in tubes as
pellets. Cell pellets were lysed in radio-immunoprecipitation
assay buffer (Nacalai Tesque, Kyoto, Japan) containing 1% (v/v)
Protease Inhibitor Cocktail (Nacalai Tesque) and then sonicated
with a Bioruptor (BM EQUIPMENT, Japan) for 9 cycles (high
intensity, 15/15-s on/off per cycle). Protein concentrations of
the lysates were measured using Pierce BCA Protein Assay
Kit (Thermo Fisher Scientific, USA) following the manufac-
turer’s instructions. Protein lysate (5 and 1 μg, for SMCHD1
and β-Actin) were mixed with NuPAGE LDS Sample Buffer and
NuPAGE Sample Reducing Agent (Thermo Fisher Scientific) and
heated at 70◦C for 10 min. Samples were then separated on
a 3–8% NuPAGE Novex tris-acetate mini gel (Thermo Fisher
Scientific) at 150 V for 60 min with the addition of NuPAGE
antioxidant (Thermo Fisher Scientific) during electrophoresis.
The fractionated proteins were transferred to a polyvinylidene
difluoride (PVDF) membrane using an iBlot system (Thermo
Fisher Scientific) with the program, P0, 9 min. The membrane
was blocked with Blocking One (Nacalai Tesque) and incubated
with primary antibody against SMCHD1 (Sigma-Aldrich, USA)
at 4◦C overnight, otherwise the membrane was blocked
overnight for β-Actin. After three washes with PBST (containing
0.1% Tween-20), the membrane was incubated for 1 h at
room temperature with peroxidase labeled anti-rabbit IgG
antibody (Vector Laboratories, USA) as a secondary antibody
for SMCHD1 or with anti-β-Actin−Peroxidase antibody (Sigma-
Aldrich, USA). Detection was carried out with SuperSignal West
Femto substrate (Thermo Fisher Scientific). Visualization of
images was performed by ImageQuant LAS 4000 system (GE
Healthcare Life Science, UK). Images were analyzed with ImageJ
(https://imagej.nih.gov/ij/) to calculate relative band intensity.
ChIP and ChIP qPCR analysis
ChIP analysis was performed by using an EpiScope ChIP Kit
(TAKARA, Japan) according to the manufacturer’s instructions
with partial modifications. Briefly, 2–5 × 106 cells of each iPSC
clone were plated and differentiated in 10 cm dishes to obtain
equally confluent myocytes. The cells were cross-linked for
5 min at room temperature with 1% formaldehyde and lysed,
and the lysates were sonicated with a Bioruptor for 12 cycles
(high intensity, 30/30-s on/off per cycle). Fragmented lysates
were incubated with antibodies conjugated to mouse IgG
magnetic beads (TAKARA) or Dynabeads Protein G (Thermo
Fisher Scientific) overnight. The beads were precipitated and
washed in a series of buffers supplied in the kit and with
DynaMag (Thermo Fisher Scientific). Immunoprecipitated beads
and 10% of the input chromatin was purified by reversing
the crosslink and treating with RNase A and Proteinase K
according to the manufacturer’s instructions. RT-qPCR followed
by the Ct method was used to quantify the D4Z4 elements.
Relative % input was calculated by dividing the amount of
immunoprecipitated chromatin by that of the input and then
normalizing relative to the F2 sample. The following primer pair
was used for D4Z4 elements: 5′-CCGCGTCCGTCCGTGAAA-3′ and
5′-TCCGTCGCCGTCCTCGTC-3′ (4).
DNA methylation analysis
Genomic DNA was extracted using a GenElute Mammalian
Genomic DNA Miniprep Kit (Sigma-Aldrich, USA) as per the
manufacturer’s protocol, and 500 ng–1 μg of DNA was treated
with bisulfite by using an EpiTect DNA bisulfite kit (QIAGEN,
Germany) according to the manufacturer’s guidelines. For the F1
clone, the methylation level of the FSHD allele was quantified
using the pyrosequencing technique as described in (34). Briefly,
PCR was performed using a PyroMark PCR Kit (QIAGEN), and
10 μL of the biotinylated PCR product was affinity purified
using Streptavidin Sepharose High Performance (GE Healthcare
Life Science) and PyroMark Q24 Advanced CpG Reagents (QIA-
GEN). For the F2 isogenic controls IC#1 and IC#2, PCR and DNA
methylation analysis of the 4qA distal region were performed
according to the protocol of the 4qA BSS assay as described in
(52) for QUMA online software (http://quma.cdb.riken.jp/index_j.
html) (53); the analysis was performed using the default
parameters.
Reagents
Hydrogen peroxide mixed with a stabilizer (H2O2, Sigma) was
added at various concentrations by diluting a 1 mM stock imme-
diately before use on day 8 of myocyte differentiation after the
depletion of 2ME for 1 day. N-acetylcysteine (NAC) was dissolved
in water, and the pH was adjusted to 7.0. NAC was added to
the cells 1 h before H2O2 stimulation. KU-55933 (Selleck Chem-
icals, USA), VE-821 (AdooQ BioScience, USA), NU-7441 (Selleck
Chemicals), PD0325901 (Cayman Chemical, USA), SP600125 (Sel-
leck Chemicals) and SB203580 (Sigma) were dissolved in DMSO
(Sigma) and added 1 h before H2O2 stimulation. MMC was added
at various concentration for 2 or 2 and a half h and then washed
once and replaced with medium.
UV-C irradiation
For the light source of UV-C, the lamps inside the laminar flow
cabinet were used. Myocytes that were differentiated on 6 cm
dishes were washed once, and medium was replaced with PBS.
Myocytes were then positioned on a fixed position inside the
laminar flow cabinet, exposed to UV-C, andwashed once. Finally,
PBS was replaced with medium.
Supplementary Material
Supplementary Material is available at HMG online.
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